

The Centers for Medicare & Medicaid Services' Office of Research, Development, and Information (ORDI) strives to make information available to all. Nevertheless, portions of our files including charts, tables, and graphics may be difficult to read using assistive technology.

Persons with disabilities experiencing problems accessing portions of any file should contact ORDI through e-mail at ORDI_508_Compliance@cms.hhs.gov.

**STATISTICAL COMPENDIUM:
MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2005
GEORGIA**

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP

TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS

FOR DUAL ELIGIBLE BENEFICIARIES

TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP

TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC

TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

SUPPLEMENTAL TABLES

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES

SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65

SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER

SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74

SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84

SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLES

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES
APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES
APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE ND.2
CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{a, b}
NONDUAL BENEFICIARIES, GEORGIA, 2005

Beneficiary Characteristics	Number of Beneficiaries						Number of Benefit Months					
	All	Aged	Disabled	Adults	Children	Other/ Unknown	All	Aged	Disabled	Adults	Children	Other/ Unknown
All	1,574,358	3,978	159,942	314,160	1,093,012	3,266	13,818,465	36,399	1,658,859	2,236,667	9,854,074	32,466
Age												
5 and younger	510,763	0	10,953	57	499,752	1	4,497,323	0	114,122	336	4,382,853	12
6-14	455,072	0	25,022	206	429,844	0	4,300,775	0	276,409	1,278	4,023,088	0
15-20	217,570	0	16,710	38,154	162,615	91	1,899,260	0	183,398	274,265	1,440,843	754
21-44	305,564	0	43,857	259,236	773	1,698	2,315,652	0	455,884	1,836,240	7,029	16,499
45-64	78,739	0	60,793	16,468	14	1,464	741,208	0	601,673	124,329	128	15,078
65-74	3,593	1,553	1,997	31	0	12	34,401	13,469	20,640	169	0	123
75-84	2,132	1,623	506	3	0	0	21,195	15,561	5,612	22	0	0
85 and older	924	802	104	5	13	0	8,648	7,369	1,121	28	130	0
Unknown	1	0	0	0	1	0	3	0	0	0	3	0
Gender												
Female	915,031	2,543	81,085	287,166	540,974	3,263	7,864,913	23,413	852,025	2,065,694	4,891,334	32,447
Male	659,271	1,434	78,857	26,989	551,988	3	5,953,123	12,984	806,834	170,946	4,962,340	19
Unknown	56	1	0	5	50	0	429	2	0	27	400	0
Race												
White	640,303	1,262	53,009	138,884	445,424	1,724	5,413,077	10,587	535,685	917,449	3,932,047	17,309
African American	788,118	1,345	69,960	166,530	549,159	1,124	7,133,017	12,237	731,876	1,269,659	5,108,212	11,033
Other/unknown	145,937	1,371	36,973	8,746	98,429	418	1,272,371	13,575	391,298	49,559	813,815	4,124
Use of Nursing Facilities^c												
Entire year	2,308	492	1,815	1	0	0	23,300	4,869	18,429	2	0	0
Part year	1,509	271	1,223	13	1	1	14,556	2,268	12,155	112	9	12
None	1,570,541	3,215	156,904	314,146	1,093,011	3,265	13,780,609	29,262	1,628,275	2,236,553	9,854,065	32,454
Maintenance Assistance Status												
Cash	508,162	1,484	136,983	132,942	236,753	0	4,794,088	16,100	1,470,250	1,034,951	2,272,787	0
Medically needy	4,516	1,094	3,366	7	49	0	25,666	8,568	16,933	17	148	0
Poverty-related	777,811	15	45	119,078	655,407	3,266	6,654,526	158	409	696,518	5,924,975	32,466
Other/unknown	283,869	1,385	19,548	62,133	200,803	0	2,344,185	11,573	171,267	505,181	1,656,164	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	1,574,358	3,978	159,942	314,160	1,093,012	3,266	13,818,465	36,399	1,658,859	2,236,667	9,854,074	32,466
FFS part year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0

Source: Data for this table are from the MAX 2005 file for Georgia, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3
ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{a, b}
NONDUAL BENEFICIARIES, GEORGIA, 2005

Beneficiary Characteristics	Percentage with at Least One Rx	Mean Number of Rx	Mean Rx \$	\$ per Rx	Mean \$, All Medicaid FFS \$ ^c	Rx \$ as a Percentage of All Medicaid FFS \$ ^d	Number of Beneficiaries
All	64.2	7.4	\$429	\$58	\$2,650	16.2	1,574,358
Age							
5 and younger	67.5	4.8	212	44	1,997	10.6	510,763
6-14	57.2	4.4	283	65	1,298	21.8	455,072
15-20	58.6	5.0	329	65	2,156	15.2	217,570
21-44	69.6	9.8	575	59	3,909	14.7	305,564
45-64	76.4	36.0	2,259	63	10,337	21.9	78,739
65-74	79.6	35.9	2,012	56	13,153	15.3	3,593
75-84	78.9	35.9	1,853	52	10,884	17.0	2,132
85 and older	77.8	34.7	1,630	47	14,650	11.1	924
Unknown	0.0	0.0	0	0	0	0.0	1
Basis of Eligibility^e							
Aged	76.2	30.8	1,623	53	11,821	13.7	3,978
Disabled	75.8	27.6	2,145	78	10,488	20.5	159,942
Adults	69.5	7.6	312	41	2,832	11.0	314,160
Children	60.9	4.2	204	48	1,395	14.7	1,093,012
Unknown	80.3	20.2	1,291	64	10,240	12.6	3,266
Gender							
Female	66.4	8.1	425	53	2,750	15.4	915,031
Male	61.1	6.4	435	68	2,511	17.3	659,271
Unknown	42.9	3.0	111	37	676	16.3	56
Race							
White	69.0	8.8	491	56	2,797	17.5	640,303
African American	60.8	6.0	337	56	2,274	14.8	788,118
Other/unknown	61.7	8.9	654	74	4,038	16.2	145,937
Use of Nursing Facilities^f							
Entire year	96.9	73.1	4,768	65	51,621	9.2	2,308
Part year	95.2	62.9	4,289	68	55,261	7.8	1,509
None	64.1	7.2	419	58	2,528	16.6	1,570,541
Maintenance Assistance Status							
Cash	67.5	12.5	826	66	4,161	19.9	508,162
Medically needy	65.4	20.0	1,499	75	14,654	10.2	4,516
Poverty related	61.7	4.3	191	45	1,582	12.1	777,811
Other/unknown	65.2	6.5	351	54	2,680	13.1	283,869

Source: Data for this table are from the MAX 2005 file for Georgia, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a, b}
 NONDUAL BENEFICIARIES, GEORGIA, 2005

Beneficiary Characteristics	Mean Number of Rx	Mean Rx \$	Rx \$ as a Percentage of All Medicaid FFS \$ ^c	Number of Rx, Percentage with:						Mean \$, All Medicaid FFS \$ ^d	Number	
				None	More than 0, but 1 or Less	More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less	More than 10		Beneficiaries	Benefit Months
All	0.8	\$49	16.2	35.8	50.2	6.8	5.1	1.7	0.4	\$302	1,574,358	13,818,465
Age												
5 and younger	0.5	24	10.6	32.5	59.2	6.1	2.1	0.1	0.0	227	510,763	4,497,323
6-14	0.5	30	21.8	42.8	49.8	4.5	2.7	0.3	0.0	137	455,072	4,300,775
15-20	0.6	38	15.2	41.4	48.5	6.0	3.5	0.5	0.0	247	217,570	1,899,260
21-44	1.3	76	14.7	30.4	46.1	10.9	9.4	2.8	0.4	516	305,564	2,315,652
45-64	3.8	240	21.9	23.6	18.7	10.3	23.9	18.0	5.6	1,098	78,739	741,208
65-74	3.8	210	15.3	20.4	17.2	11.3	27.3	18.9	5.0	1,374	3,593	34,401
75-84	3.6	186	17.0	21.1	16.4	10.3	29.4	19.6	3.2	1,095	2,132	21,195
85 and older	3.7	174	11.1	22.2	14.2	11.1	27.4	19.8	5.3	1,565	924	8,648
Unknown	0.0	0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	0	1	3
Basis of Eligibility^e												
Aged	3.4	177	13.7	23.8	18.4	11.3	27.2	15.7	3.6	1,292	3,978	36,399
Disabled	2.7	207	20.5	24.2	29.7	11.0	19.7	12.0	3.4	1,011	159,942	1,658,859
Adults	1.1	44	11.0	30.5	49.2	10.7	7.6	1.7	0.2	398	314,160	2,236,667
Children	0.5	23	14.7	39.1	53.7	5.0	2.1	0.1	0.0	155	1,093,012	9,854,074
Unknown	2.0	130	12.6	19.7	36.4	14.1	20.5	8.3	1.0	1,030	3,266	32,466
Gender												
Female	0.9	49	15.4	33.6	50.9	7.3	5.6	2.1	0.5	320	915,031	7,864,913
Male	0.7	48	17.3	38.9	49.2	6.0	4.4	1.2	0.2	278	659,271	5,953,123
Unknown	0.4	14	16.3	57.1	35.7	5.4	1.8	0.0	0.0	88	56	429
Race												
White	1.0	58	17.5	31.0	51.5	8.3	6.4	2.2	0.6	331	640,303	5,413,077
African American	0.7	37	14.8	39.2	50.1	5.6	3.8	1.2	0.2	251	788,118	7,133,017
Other/unknown	1.0	75	16.2	38.3	45.6	6.8	6.3	2.4	0.6	463	145,937	1,272,371
Use of Nursing Facilities^f												
Entire year	7.2	472	9.2	3.1	4.0	6.1	25.7	40.6	20.6	5,113	2,308	23,300
Part year	6.5	445	7.8	4.8	6.2	7.4	30.4	35.3	16.0	5,729	1,509	14,556
None	0.8	48	16.6	35.9	50.3	6.8	5.0	1.6	0.4	288	1,570,541	13,780,609
Maintenance Assistance Status												
Cash	1.3	88	19.9	32.5	45.5	7.8	9.0	4.2	1.1	441	508,162	4,794,088
Medically needy	3.5	264	10.2	34.6	14.2	9.7	22.3	15.4	3.8	2,578	4,516	25,666
Poverty related	0.5	22	12.1	38.3	53.2	5.8	2.5	0.2	0.0	185	777,811	6,654,526
Other/unknown	0.8	43	13.1	34.8	51.2	7.5	5.0	1.2	0.2	325	283,869	2,344,185

Source: Data for this table are from the MAX 2005 file for Georgia, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.5
AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{a, b, c}
NONDUAL BENEFICIARIES, GEORGIA, 2005

Beneficiary Characteristics	All Rx			Patented Brand-Name Drugs			Off-Patent Brand-Name Drugs			Generic Drugs		
	Number of Rx	Rx \$	\$ per Rx	Number of Rx	Rx \$	\$ per Rx	Number of Rx	Rx \$	\$ per Rx	Number of Rx	Rx \$	\$ per Rx
All	0.8	\$49	\$58	0.3	\$37	\$124	0.0	\$2	\$57	0.5	\$10	\$19
Age												
5 and younger	0.5	24	44	0.2	17	106	0.0	2	37	0.3	6	17
6-14	0.5	30	65	0.2	24	112	0.0	2	57	0.2	5	21
15-20	0.6	38	65	0.2	30	134	0.0	2	56	0.3	6	19
21-44	1.3	76	59	0.4	57	139	0.1	4	69	0.8	15	18
45-64	3.8	240	63	1.4	181	131	0.1	9	89	2.3	49	21
65-74	3.8	210	56	1.5	165	110	0.1	6	57	2.1	39	18
75-84	3.6	186	52	1.5	144	99	0.1	6	57	2.0	36	18
85 and older	3.7	174	47	1.3	129	97	0.1	8	61	2.2	37	17
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
Basis of Eligibility^d												
Aged	3.4	177	53	1.4	139	100	0.1	6	57	1.9	33	18
Disabled	2.7	207	78	1.0	165	160	0.1	8	92	1.5	34	22
Adults	1.1	44	41	0.3	30	97	0.0	3	53	0.7	11	15
Children	0.5	23	48	0.2	16	99	0.0	1	43	0.3	5	18
Unknown	2.0	130	64	0.7	101	145	0.1	4	70	1.3	24	19
Gender												
Female	0.9	49	53	0.3	36	114	0.0	3	56	0.6	11	18
Male	0.7	48	68	0.3	38	139	0.0	2	59	0.4	8	20
Unknown	0.4	14	37	0.1	10	84	0.0	1	33	0.3	4	16
Race												
White	1.0	58	56	0.4	43	117	0.0	3	58	0.6	12	19
African American	0.7	37	56	0.2	28	124	0.0	2	55	0.4	7	18
Other/unknown	1.0	75	74	0.4	61	153	0.0	3	66	0.6	12	20
Use of Nursing Facilities^e												
Entire year	7.2	472	65	2.5	360	142	0.3	19	67	4.4	93	21
Part year	6.5	445	68	2.2	327	147	0.3	21	84	4.0	96	24
None	0.8	48	58	0.3	36	124	0.0	2	57	0.5	9	19
Maintenance Assistance Status												
Cash	1.3	88	66	0.5	68	142	0.1	4	73	0.8	16	20
Medically needy	3.5	264	75	1.3	196	148	0.1	10	107	2.1	57	28
Poverty related	0.5	22	45	0.2	16	94	0.0	1	42	0.3	5	17
Other/unknown	0.8	43	54	0.3	32	113	0.0	2	51	0.5	8	18

Source: Data for this table are from the MAX 2005 file for Georgia, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Georgia, 0.4 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}
 NONDUAL BENEFICIARIES, GEORGIA, 2005

Therapeutic Category	Number of Rx per Benefit Month Among Users				\$ per Benefit Month Among Users				\$ per Rx				Users ^e			
	Patented				Off-Brand-				Patented				As a Percentage of All Benes			
	Total	Brand-Name	Brand-Name	Generic	Total	Brand-Name	Brand-Name	Generic	Total	Brand-Name	Brand-Name	Generic	Total Number of Rx	Total Rx \$	Number of Users	Number of Benefit Months
Anti-infective Agents	0.3	0.1	0.0	0.2	\$13	\$8	\$1	\$3	\$51	\$123	\$60	\$21	1,772,955	\$90,883,234	689,044	43.8
Biologicals	0.5	0.5	0.0	0.0	701	617	18	66	1342	1,242	2,950	3,369	17,612	23,630,909	3,687	0.2
Antineoplastic Agents	0.5	0.2	0.0	0.3	116	94	1	21	242	622	133	64	26,236	6,343,902	5,281	0.3
Endocrine/Metabolic Drugs	0.4	0.1	0.0	0.2	18	12	2	4	51	94	63	20	889,237	44,918,003	247,663	15.7
Cardiovascular Agents	1.1	0.4	0.0	0.7	44	34	0	9	40	81	23	14	1,177,125	46,761,356	103,896	6.6
Respiratory Agents	0.4	0.1	0.0	0.2	16	12	1	3	45	92	31	16	2,068,923	93,570,893	564,527	35.9
Gastrointestinal Agents	0.4	0.2	0.0	0.2	25	22	0	3	69	135	38	16	542,343	37,691,885	146,635	9.3
Genitourinary Agents	0.2	0.1	0.0	0.1	9	5	1	2	43	69	57	22	171,522	7,456,616	83,541	5.3
CNS Drugs	0.7	0.4	0.0	0.3	66	59	0	6	97	162	64	21	1,175,431	113,801,736	167,208	10.6
Stimulants/Anti-obesity/Anorexia	0.6	0.6	0.0	0.1	56	53	0	2	88	97	63	30	410,802	36,263,059	60,403	3.8
Miscellaneous Psychological/Neurological Agents	0.6	0.5	0.0	0.1	175	173	0	2	304	342	0	31	15,572	4,738,011	2,553	0.2
Analgesics and Anesthetics	0.4	0.0	0.0	0.3	11	4	2	5	28	164	179	15	1,326,592	37,722,816	347,614	22.1
Neuromuscular Agents	0.6	0.2	0.0	0.4	48	35	2	12	80	156	87	32	610,913	49,099,111	96,765	6.1
Nutritional Products	0.3	0.1	0.0	0.2	5	2	0	3	17	23	14	14	254,879	4,284,310	90,829	5.8
Hematological Agents	0.5	0.2	0.0	0.3	153	148	1	4	294	727	38	15	108,301	31,830,101	20,309	1.3
Topical Products	0.2	0.1	0.0	0.1	9	5	0	3	40	75	43	22	962,922	38,324,637	416,237	26.4
Miscellaneous Products	0.2	0.1	0.0	0.0	24	16	3	4	144	151	435	82	47,091	6,795,145	27,214	1.7
Unknown Therapeutic Category	0.2	0.0	0.0	0.0	6	0	0	0	35	0	0	0	28,282	1,003,102	15,985	1.0
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	11,606,738	675,118,826	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for Georgia, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Georgia, 0.4 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Nondual Beneficiaries

TABLE ND.7
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{a, b, c}
 NONDUAL BENEFICIARIES, GEORGIA, 2005

Top 10 Drug Groups	Users			Among Users			
	Total Medicaid Rx \$	Number of Users	As a Percentage of All Beneficiaries	Number of Benefit Months	Number of Rx per Benefit Month	\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$75,620,976	56,534	3.6	624,445	0.6	\$219	\$121
ANTIASTHMATIC	58,220,677	320,336	20.3	3,381,729	0.2	70	17
ANTICONVULSANT	42,273,759	59,888	3.8	647,811	0.6	110	65
STIMULANTS/ANTI-OBESITY/ANOREXIANTS	36,263,059	68,821	4.4	750,805	0.5	88	48
ANTIDEPRESSANTS	32,233,146	120,855	7.7	1,254,568	0.4	59	26
ANTIVIRAL	31,135,881	33,681	2.1	349,035	0.3	328	89
DERMATOLOGICAL	26,460,003	404,026	25.7	4,263,256	0.1	42	6
ULCER DRUGS	26,092,844	131,429	8.3	1,353,965	0.3	67	19
MISC. HEMATOLOGICAL	23,992,309	6,842	0.4	73,113	0.6	583	328
PASSIVE IMMUNIZING AGENTS	23,629,702	3,648	0.2	33,429	0.5	1,342	707
Total	375,922,356	1,206,060		12,732,156	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for Georgia, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispn.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Nondual Beneficiaries

TABLE ND.7A
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED
 AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, GEORGIA, 2005

Beneficiary Characteristics	All Top 10 Drug Groups			ANTIpsychOTICS				ANTIasthmatic				
	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month
All	3,696,540	\$375,922,356	56,534	3.6	624,445	0.6	\$121	320,336	20.3	3,381,729	0.2	\$17
Female												
All Females	2,071,498	192,171,625	29,891	3.3	326,722	0.5	112	162,493	17.8	1,709,736	0.3	17
Female, Disabled												
All Ages	910,693	102,313,770	17,815	22.0	204,016	0.6	138	33,094	40.8	376,706	0.4	30
5 and younger	22,287	4,734,602	71	1.6	817	0.4	60	2,557	56.8	29,053	0.3	26
6-14	59,713	6,401,855	1,046	12.5	12,154	0.6	110	3,021	36.0	35,073	0.3	24
15-20	42,317	5,233,659	1,068	16.7	12,346	0.6	132	1,479	23.2	17,231	0.3	25
21-44	245,355	31,748,590	6,875	29.2	79,008	0.6	133	7,014	29.8	80,529	0.3	25
45-64	520,743	52,555,986	8,431	23.1	96,118	0.6	146	18,329	50.3	207,568	0.5	34
65-74	15,815	1,305,500	245	18.0	2,681	0.7	154	564	41.5	5,762	0.5	31
75-84	3,652	283,883	64	18.1	733	0.7	120	107	30.2	1,248	0.4	30
85 and older	811	49,695	15	17.9	159	0.4	46	23	27.4	242	0.3	24
Female, Other Eligibles												
All Ages	1,160,805	89,857,855	12,076	1.4	122,706	0.4	69	129,399	15.5	1,333,030	0.2	14
5 and younger	298,052	21,549,147	223	0.1	2,444	0.4	57	57,762	23.5	602,309	0.2	13
6-14	296,708	22,028,697	2,725	1.3	30,365	0.5	86	34,056	15.9	366,179	0.2	14
15-20	140,994	11,061,128	2,274	1.9	23,872	0.5	82	11,921	10.1	122,323	0.2	12
21-44	348,491	29,056,436	5,792	2.4	55,431	0.3	56	22,329	9.3	209,116	0.2	14
45-64	58,214	4,800,369	763	5.5	7,449	0.4	54	2,760	20.0	27,134	0.3	24
65-74	5,936	483,530	64	6.3	716	0.7	150	187	18.4	1,905	0.4	29
75-84	7,459	557,607	132	13.0	1,381	0.7	99	250	24.7	2,729	0.4	30
85 and older	4,951	320,941	103	18.7	1,048	0.6	73	134	24.3	1,335	0.4	23
Male												
All Males	1,624,980	183,746,967	26,643	4.0	297,723	0.6	131	157,832	23.9	1,671,880	0.2	17
Male, Disabled												
All Ages	653,458	99,775,251	16,350	20.7	186,522	0.6	153	23,525	29.8	264,635	0.4	28
5 and younger	34,757	7,121,981	290	4.5	3,347	0.5	72	4,281	66.3	48,911	0.3	24
6-14	140,632	18,347,654	3,407	20.5	39,614	0.6	119	6,199	37.3	72,326	0.3	23
15-20	71,975	14,910,149	2,333	22.6	27,097	0.6	143	2,099	20.3	24,379	0.3	22
21-44	169,527	31,773,758	5,973	29.4	68,104	0.7	174	2,666	13.1	30,032	0.4	25
45-64	229,408	26,938,129	4,200	17.3	46,710	0.7	161	7,973	32.8	85,732	0.5	37
65-74	5,462	552,448	116	18.2	1,281	0.7	177	244	38.3	2,532	0.4	30
75-84	1,490	114,296	27	17.8	321	0.7	100	60	39.5	687	0.5	32
85 and older	207	16,836	4	20.0	48	0.6	122	3	15.0	36	0.2	10

Nondual Beneficiaries

TABLE ND.7A
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED
 AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, GEORGIA, 2005

NON-PRESCRIPTION DRUGS, 2000-2009												
All Top 10 Drug Groups				ANTIPSYCHOTICS				ANTIASTHMATIC				
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month
Male, Other Eligibles												
All Ages	971,522	83,971,716	10,293	1.8	111,201	0.5	95	134,307	23.1	1,407,245	0.2	15
5 and younger	350,493	27,659,482	569	0.2	6,376	0.4	61	77,588	30.6	806,015	0.2	15
6-14	451,974	38,449,458	6,278	2.9	69,398	0.5	95	45,496	21.1	486,839	0.2	16
15-20	118,172	11,916,971	2,600	3.1	27,707	0.5	104	8,742	10.5	91,881	0.2	15
21-44	28,883	3,931,987	561	2.5	4,992	0.4	79	1,534	6.8	13,534	0.3	20
45-64	11,130	1,216,092	118	2.9	1,089	0.4	97	564	13.6	5,112	0.4	24
65-74	3,561	295,629	63	10.9	649	0.7	118	104	18.0	1,064	0.4	31
75-84	5,129	361,845	74	12.1	719	0.7	101	203	33.1	2,102	0.6	36
85 and older	2,180	140,252	30	11.2	271	0.7	93	76	28.4	698	0.7	30
Unknown	62	3,764	0	0.0	0	0.0	0	11	19.3	113	0.1	11

Source: Data for this table are from the MAX 2005 file for Georgia, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispn.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

Nondual Beneficiaries

TABLE ND.7B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,
 BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, GEORGIA, 2005

Beneficiary Characteristics	ANTICONVULSANT					STIMULANTS/ANTI-OBESITY/ANOREXIANTS					ANTIDEPRESSANTS				
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month
All	59,888	3.8	647,811	0.6	\$65	68,821	4.4	750,805	0.5	\$48	120,855	7.7	1,254,568	0.4	\$26
Female															
All Females	37,665	4.1	404,289	0.6	61	20,558	2.2	223,956	0.5	47	90,496	9.9	929,315	0.4	26
Female, Disabled															
All Ages	21,014	25.9	238,987	0.7	73	3,414	4.2	39,655	0.5	49	35,036	43.2	397,916	0.5	31
5 and younger	533	11.8	6,175	0.7	93	105	2.3	1,179	0.4	39	41	0.9	460	0.3	7
6-14	1,577	18.8	18,343	0.8	106	2,041	24.3	23,757	0.6	48	859	10.2	9,936	0.5	22
15-20	1,269	19.9	14,669	0.8	109	687	10.8	8,058	0.5	50	1,385	21.7	15,878	0.4	26
21-44	7,111	30.2	81,090	0.7	79	325	1.4	3,747	0.5	51	11,519	48.9	131,218	0.5	29
45-64	10,170	27.9	114,849	0.6	58	253	0.7	2,894	0.5	53	20,671	56.7	234,338	0.6	32
65-74	274	20.1	2,969	0.7	38	3	0.2	20	0.6	27	440	32.4	4,705	0.6	31
75-84	67	18.9	751	0.6	37	0	0.0	0	0.0	0	96	27.1	1,094	0.6	33
85 and older	13	15.5	141	0.6	28	0	0.0	0	0.0	0	25	29.8	287	0.6	32
Female, Other Eligibles															
All Ages	16,651	2.0	165,302	0.4	45	17,144	2.1	184,301	0.5	46	55,460	6.7	531,399	0.3	22
5 and younger	673	0.3	7,167	0.4	45	962	0.4	10,687	0.3	30	169	0.1	1,881	0.3	8
6-14	2,086	1.0	22,644	0.5	65	12,690	5.9	137,136	0.6	47	4,395	2.0	48,168	0.4	20
15-20	2,132	1.8	21,686	0.4	60	2,463	2.1	26,435	0.5	48	8,329	7.1	83,933	0.3	20
21-44	10,061	4.2	96,799	0.4	38	930	0.4	9,081	0.5	46	37,413	15.6	346,979	0.3	22
45-64	1,432	10.4	14,164	0.4	38	96	0.7	929	0.5	48	4,576	33.1	44,333	0.4	28
65-74	105	10.3	1,131	0.5	35	0	0.0	0	0.0	0	210	20.6	2,189	0.6	28
75-84	109	10.8	1,185	0.7	37	3	0.3	33	0.7	39	224	22.1	2,430	0.6	32
85 and older	53	9.6	526	0.9	55	0	0.0	0	0.0	0	144	26.1	1,486	0.7	30
Male															
All Males	22,223	3.4	243,522	0.6	72	48,262	7.3	526,840	0.6	49	30,358	4.6	325,244	0.5	25
Male, Disabled															
All Ages	15,004	19.0	169,250	0.7	80	9,853	12.5	114,325	0.6	53	16,533	21.0	184,463	0.5	28
5 and younger	734	11.4	8,495	0.6	82	451	7.0	5,147	0.4	33	95	1.5	1,106	0.4	10
6-14	2,685	16.2	31,090	0.7	87	6,973	41.9	80,786	0.6	54	2,186	13.1	25,360	0.5	22
15-20	1,832	17.7	21,114	0.8	104	2,054	19.9	24,057	0.6	54	1,768	17.1	20,317	0.5	27
21-44	4,920	24.2	55,237	0.8	90	284	1.4	3,297	0.7	54	5,186	25.5	57,836	0.5	31
45-64	4,718	19.4	52,170	0.6	56	91	0.4	1,038	0.5	56	7,155	29.4	78,281	0.5	29
65-74	93	14.6	889	0.7	59	0	0.0	0	0.0	0	111	17.4	1,192	0.6	33
75-84	21	13.8	243	0.6	52	0	0.0	0	0.0	0	27	17.8	314	0.6	29
85 and older	1	5.0	12	0.9	23	0	0.0	0	0.0	0	5	25.0	57	0.7	20

Nondual Beneficiaries

TABLE ND.7B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,
 BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, GEORGIA, 2005

Beneficiary Characteristics	ANTICONVULSANT					STIMULANTS/ANTI-OBESITY/ANOREXIANTS					ANTIDEPRESSANTS				
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month
Male, Other Eligibles															
All Ages	7,219	1.2	74,272	0.5	53	38,409	6.6	412,515	0.5	48	13,825	2.4	140,781	0.4	22
5 and younger	978	0.4	10,572	0.4	45	2,433	1.0	26,995	0.4	27	253	0.1	2,817	0.3	9
6-14	3,009	1.4	32,565	0.5	58	30,684	14.2	329,536	0.6	49	6,102	2.8	66,802	0.4	20
15-20	1,460	1.8	15,232	0.5	62	5,125	6.2	54,632	0.5	51	3,753	4.5	38,703	0.4	23
21-44	1,242	5.5	10,916	0.4	38	137	0.6	1,080	0.5	44	2,668	11.8	22,822	0.4	23
45-64	354	8.6	3,205	0.5	42	25	0.6	231	0.5	56	772	18.7	6,869	0.4	24
65-74	69	11.9	684	0.7	43	0	0.0	0	0.0	0	101	17.5	999	0.6	35
75-84	85	13.8	888	0.6	39	2	0.3	16	0.6	9	127	20.7	1,312	0.5	29
85 and older	22	8.2	210	0.5	20	3	1.1	25	0.2	10	49	18.3	457	0.7	44
Unknown	0	0.0	0	0.0	0	1	1.8	9	0.8	114	1	1.8	9	0.1	4

Source: Data for this table are from the MAX 2005 file for Georgia, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispn.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

Nondual Beneficiaries

TABLE ND.7C
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,
 BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, GEORGIA, 2005

Beneficiary Characteristics	ANTIVIRAL					DERMATOLOGICAL					ULCER DRUGS				
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month
All	33,681	2.1	349,035	0.3	\$89	404,026	25.7	4,263,256	0.1	\$6	131,429	8.3	1,353,965	0.3	\$19
Female															
All Females	22,369	2.4	228,364	0.3	77	234,832	25.7	2,473,071	0.2	7	88,054	9.6	911,608	0.3	20
Female, Disabled															
All Ages	5,248	6.5	59,506	0.4	176	27,494	33.9	318,368	0.2	9	30,315	37.4	346,427	0.4	31
5 and younger	127	2.8	1,444	0.2	16	1,948	43.3	22,185	0.1	5	869	19.3	9,393	0.3	22
6-14	311	3.7	3,622	0.3	88	3,108	37.0	36,351	0.1	6	881	10.5	10,229	0.4	30
15-20	235	3.7	2,769	0.3	91	2,228	34.9	26,012	0.2	8	889	13.9	10,272	0.3	19
21-44	2,311	9.8	25,976	0.4	191	7,144	30.3	83,111	0.2	8	7,790	33.1	89,591	0.3	25
45-64	2,218	6.1	25,217	0.4	192	12,444	34.1	143,696	0.2	11	18,957	52.0	216,457	0.5	34
65-74	44	3.2	454	0.4	112	479	35.2	5,391	0.2	12	720	52.9	8,078	0.5	30
75-84	2	0.6	24	0.1	18	115	32.5	1,350	0.2	11	168	47.5	1,935	0.5	24
85 and older	0	0.0	0	0.0	0	28	33.3	272	0.3	13	41	48.8	472	0.6	31
Female, Other Eligibles															
All Ages	17,121	2.1	168,858	0.2	42	207,338	24.9	2,154,703	0.1	6	57,739	6.9	565,181	0.2	13
5 and younger	2,551	1.0	27,334	0.1	5	98,991	40.2	1,027,291	0.1	5	14,148	5.7	129,911	0.2	8
6-14	2,891	1.3	31,458	0.1	19	51,507	24.0	561,810	0.1	7	7,495	3.5	81,713	0.2	10
15-20	2,503	2.1	25,062	0.2	27	23,159	19.7	242,210	0.2	9	7,155	6.1	72,911	0.2	9
21-44	8,677	3.6	80,021	0.3	63	30,325	12.7	289,031	0.2	8	24,493	10.2	235,650	0.2	16
45-64	447	3.2	4,426	0.3	129	2,578	18.7	26,116	0.2	9	3,521	25.5	35,109	0.4	28
65-74	26	2.6	260	0.3	140	268	26.4	2,923	0.2	13	374	36.8	3,972	0.4	27
75-84	15	1.5	172	0.3	98	299	29.5	3,223	0.2	15	359	35.5	3,956	0.5	25
85 and older	11	2.0	125	0.2	8	211	38.2	2,099	0.3	13	194	35.1	1,959	0.6	30
Male															
All Males	11,312	1.7	120,671	0.3	113	169,174	25.7	1,789,972	0.1	6	43,371	6.6	442,323	0.3	18
Male, Disabled															
All Ages	4,609	5.8	49,848	0.5	243	19,233	24.4	220,929	0.2	8	14,735	18.7	164,880	0.4	30
5 and younger	160	2.5	1,860	0.2	23	2,757	42.7	31,715	0.1	5	1,119	17.3	12,427	0.3	22
6-14	392	2.4	4,593	0.3	80	4,456	26.8	52,267	0.1	6	1,259	7.6	14,759	0.3	27
15-20	181	1.8	2,067	0.2	71	2,665	25.8	31,055	0.2	9	877	8.5	10,072	0.3	24
21-44	1,956	9.6	20,456	0.6	271	3,937	19.4	44,891	0.2	9	3,439	16.9	38,739	0.4	28
45-64	1,901	7.8	20,653	0.6	288	5,223	21.5	58,779	0.2	12	7,739	31.8	85,526	0.5	33
65-74	15	2.4	171	0.6	211	144	22.6	1,650	0.2	10	230	36.1	2,514	0.5	28
75-84	1	0.7	12	0.1	6	42	27.6	476	0.2	7	61	40.1	711	0.4	26
85 and older	3	15.0	36	0.1	5	9	45.0	96	0.2	12	11	55.0	132	0.7	48

Nondual Beneficiaries

TABLE ND.7C
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,
 BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, GEORGIA, 2005

Beneficiary Characteristics	ANTIVIRAL					DERMATOLOGICAL					ULCER DRUGS				
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month
Male, Other Eligibles															
All Ages	6,703	1.2	70,823	0.1	22	149,941	25.8	1,569,043	0.1	6	28,636	4.9	277,443	0.2	11
5 and younger	2,657	1.0	28,536	0.1	6	94,872	37.4	976,294	0.1	5	16,183	6.4	148,464	0.2	9
6-14	2,721	1.3	29,183	0.1	17	39,058	18.1	425,734	0.1	6	6,336	2.9	69,315	0.2	10
15-20	893	1.1	9,167	0.2	26	13,552	16.3	144,185	0.2	10	2,764	3.3	28,930	0.2	10
21-44	316	1.4	2,812	0.3	129	1,573	7.0	13,876	0.2	10	2,096	9.3	18,624	0.3	25
45-64	94	2.3	875	0.4	301	466	11.3	4,503	0.2	12	739	17.9	6,690	0.4	29
65-74	4	0.7	47	0.1	10	130	22.5	1,375	0.2	14	198	34.3	2,046	0.4	32
75-84	8	1.3	96	0.1	6	197	32.1	2,100	0.3	12	228	37.1	2,436	0.4	26
85 and older	10	3.7	107	0.2	50	93	34.7	976	0.2	11	92	34.3	938	0.6	33
Unknown	0	0.0	0	0.0	0	20	35.1	213	0.2	5	4	7.0	34	0.1	9

Source: Data for this table are from the MAX 2005 file for Georgia, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispn.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Nondual Beneficiaries

TABLE ND.7D
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS
 SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, GEORGIA, 2005

Beneficiary Characteristics	MISC. HEMATOLOGICAL					PASSIVE IMMUNIZING AGENTS					Number of Beneficiaries	Number of Benefit Months
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month		
All	6,842	0.4	73,113	0.6	\$328	3,648	0.2	33,429	0.5	\$707	1,574,358	13,818,465
Female												
All Females	4,019	0.4	43,585	0.6	90	1,813	0.2	16,759	0.5	678	915,031	7,864,913
Female, Disabled												
All Ages	3,264	4.0	36,147	0.6	86	477	0.6	4,811	0.6	895	81,085	852,025
5 and younger	2	0.0	21	0.1	40	439	9.8	4,408	0.5	673	4,499	46,366
6-14	8	0.1	92	0.6	599	4	0.0	48	0.6	782	8,397	93,367
15-20	8	0.1	96	0.4	36	7	0.1	77	0.7	1,262	6,387	70,180
21-44	307	1.3	3,390	0.5	74	18	0.1	188	0.9	3,614	23,545	249,968
45-64	2,738	7.5	30,394	0.6	87	9	0.0	90	1.2	5,844	36,459	372,945
65-74	150	11.0	1,587	0.6	65	0	0.0	0	0.0	0	1,360	14,371
75-84	42	11.9	476	0.6	68	0	0.0	0	0.0	0	354	3,925
85 and older	9	10.7	91	0.5	62	0	0.0	0	0.0	0	84	903
Female, Other Eligibles												
All Ages	755	0.1	7,438	0.5	111	1,336	0.2	11,948	0.5	591	833,946	7,012,888
5 and younger	2	0.0	24	1.8	14,607	1,212	0.5	10,819	0.5	605	246,266	2,162,696
6-14	10	0.0	107	0.3	78	4	0.0	48	1.1	2,006	214,411	2,009,322
15-20	12	0.0	110	0.2	611	27	0.0	262	0.1	152	117,694	988,205
21-44	281	0.1	2,641	0.3	43	92	0.0	807	0.2	461	239,181	1,717,361
45-64	253	1.8	2,457	0.5	57	1	0.0	12	0.3	388	13,813	111,593
65-74	58	5.7	601	0.7	63	0	0.0	0	0.0	0	1,017	8,926
75-84	72	7.1	795	0.7	67	0	0.0	0	0.0	0	1,012	9,797
85 and older	67	12.1	703	0.7	73	0	0.0	0	0.0	0	552	4,988
Male												
All Males	2,823	0.4	29,528	0.6	680	1,835	0.3	16,670	0.6	736	659,270	5,953,120
Male, Disabled												
All Ages	2,296	2.9	24,696	0.6	648	477	0.6	4,953	0.6	864	78,857	806,834
5 and younger	17	0.3	195	0.6	4,496	447	6.9	4,620	0.6	749	6,454	67,756
6-14	30	0.2	353	0.5	8,922	12	0.1	126	0.8	1,584	16,625	183,042
15-20	38	0.4	440	0.4	12,546	9	0.1	107	1.0	2,555	10,323	113,218
21-44	160	0.8	1,774	0.5	2,794	8	0.0	95	0.7	2,515	20,312	205,916
45-64	1,967	8.1	21,011	0.6	68	1	0.0	5	1.0	21,467	24,334	228,728
65-74	59	9.3	642	0.5	58	0	0.0	0	0.0	0	637	6,269
75-84	23	15.1	257	0.5	63	0	0.0	0	0.0	0	152	1,687
85 and older	2	10.0	24	0.5	70	0	0.0	0	0.0	0	20	218

Nondual Beneficiaries

TABLE ND.7D
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS
 SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, GEORGIA, 2005

Beneficiary Characteristics	MISC. HEMATOLOGICAL					PASSIVE IMMUNIZING AGENTS					Number of Beneficiaries	Number of Benefit Months
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month		
Male, Other Eligibles												
All Ages	527	0.1	4,832	0.6	845	1,358	0.2	11,717	0.5	682	580,413	5,146,286
5 and younger	25	0.0	270	0.3	1,996	1,348	0.5	11,625	0.5	673	253,501	2,220,143
6-14	26	0.0	260	0.4	3,692	4	0.0	37	1.1	2,375	215,634	2,015,015
15-20	17	0.0	172	0.5	5,800	4	0.0	38	0.7	1,393	83,163	727,645
21-44	129	0.6	1,080	0.5	1,222	1	0.0	5	0.8	1,442	22,522	142,383
45-64	167	4.0	1,462	0.6	105	1	0.0	12	0.2	1,494	4,133	27,942
65-74	57	9.9	538	0.6	70	0	0.0	0	0.0	0	578	4,833
75-84	76	12.4	759	0.7	68	0	0.0	0	0.0	0	614	5,786
85 and older	30	11.2	291	0.7	78	0	0.0	0	0.0	0	268	2,539
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	57	432

Source: Data for this table are from the MAX 2005 file for Georgia, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy; \$ = Medicaid reimbursement.

Nondual Beneficiaries

TABLE ND.8
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,
 BY BENEFICIARY CHARACTERISTIC^{a, b}
 NONDUAL BENEFICIARIES, GEORGIA, 2005

Beneficiary Characteristics	Rx \$ per Benefit Month	Number of Rx per Benefit Month	Number of All-Year Nursing Facility Residents	Benefit Months Among All-Year Nursing Facility Residents
All	\$472	7.2	2,308	23,300
Age				
0-64	515	7.5	1,618	16,330
65-74	473	7.7	245	2,534
75-84	360	6.3	228	2,368
85 and older	268	5.5	217	2,068
Unknown	0	0.0	0	0
Gender				
Female	470	7.5	1,240	12,655
Male	475	7.0	1,068	10,645
Unknown	0	0.0	0	0
Race				
White	479	7.7	912	8,959
African American	469	6.8	1,196	12,265
Other/unknown	463	7.6	200	2,076
Basis of Eligibility^c				
Aged	351	6.4	492	4,869
Disabled	505	7.5	1,815	18,429
Adults	0	0.0	1	2
Children	0	0.0	0	0
Unknown	0	0.0	0	0

Source: Data for this table are from the MAX 2005 file for Georgia, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2005 Medicaid enrollment. A total of 1,509 beneficiaries who were in nursing facilities for part of their enrollment and their 14,556 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

Nondual Beneficiaries

TABLE ND.9
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,
 BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d, e}
 NONDUAL BENEFICIARIES, GEORGIA, 2005

Therapeutic Category	Number of Rx per Benefit Month Among Users				\$ per Benefit Month Among Users				\$ per Rx				Users				
	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Months
Anti-infective Agents	0.5	0.2	0.0	0.2	\$61	\$49	\$5	\$7	\$127	\$260	\$109	\$27	7,367	\$937,384	1,469	63.6	15,436
Biologicals	0.0	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0	0.0	0
Antineoplastic Agents	0.5	0.1	0.0	0.4	116	80	0	35	232	861	72	88	748	173,636	154	6.7	1,501
Endocrine/Metabolic Drugs	1.2	0.5	0.1	0.6	61	47	5	10	51	92	44	16	12,713	643,221	1,007	43.6	10,525
Cardiovascular Agents	2.1	0.6	0.0	1.5	75	50	0	24	35	85	22	16	34,506	1,208,073	1,583	68.6	16,163
Respiratory Agents	0.8	0.2	0.0	0.5	31	22	0	8	40	91	43	16	7,742	307,415	969	42.0	9,975
Gastrointestinal Agents	1.1	0.3	0.0	0.8	52	40	0	12	45	129	39	14	15,500	702,672	1,313	56.9	13,585
Genitourinary Agents	0.6	0.4	0.0	0.2	39	33	1	6	67	84	47	32	2,800	187,718	443	19.2	4,774
CNS Drugs	1.8	1.0	0.0	0.8	189	169	1	19	105	169	63	24	32,879	3,444,030	1,749	75.8	18,240
Stimulants/Anti-obesity/Anorexia	0.9	0.2	0.0	0.7	29	18	0	12	33	85	0	17	163	5,355	17	0.7	183
Miscellaneous Psychological/Neurological Agents	0.9	0.9	0.0	0.0	174	174	0	0	192	193	0	58	2,808	539,809	301	13.0	3,100
Analgesics and Anesthetics	1.1	0.1	0.1	0.8	50	21	14	16	45	137	115	19	14,444	655,039	1,260	54.6	12,999
Neuromuscular Agents	1.4	0.4	0.1	1.0	94	53	4	37	67	151	48	38	17,698	1,187,385	1,193	51.7	12,616
Nutritional Products	0.7	0.0	0.0	0.7	12	0	1	11	17	23	23	16	4,867	80,469	662	28.7	6,724
Hematological Agents	1.1	0.4	0.1	0.6	94	83	2	9	88	204	25	16	6,726	589,902	640	27.7	6,288
Topical Products	0.5	0.2	0.0	0.3	23	14	2	7	45	77	45	24	7,004	312,641	1,298	56.2	13,866
Miscellaneous Products	0.3	0.1	0.0	0.2	17	8	0	8	56	128	0	36	396	22,271	121	5.2	1,314
Unknown Therapeutic Category	0.3	0.0	0.0	0.0	9	0	0	0	26	0	0	0	318	8,334	97	4.2	980
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	168,679	11,005,354	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for Georgia, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 1,509 beneficiaries who were in nursing facilities for part of their enrollment and their 14,556 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

In Georgia, 0.4 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Nondual Beneficiaries

TABLE ND.10
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,
 BY TOP-10 DRUG GROUP^{a, b, c, d}
 NONDUAL BENEFICIARIES, GEORGIA, 2005

Top 10 Drug Groups in Nursing Facilities	Total Medicaid Rx \$	Users			Among Users		
		Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Months per	Number of Rx per Benefit Month	\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$2,529,715	1,364	59.1	14,966	0.8	\$200	\$169
ANTICONVULSANT	1,013,513	1,239	53.7	13,529	1.0	75	75
ANTIDEPRESSANTS	791,482	1,482	64.2	15,949	0.8	61	50
ANTIDIABETIC	625,292	1,151	49.9	12,338	1.0	51	51
ULCER DRUGS	540,421	1,389	60.2	14,867	0.8	48	36
ANTIVIRAL	513,088	163	7.1	1,727	0.6	497	297
MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL	539,809	338	14.6	3,546	0.8	192	152
ANTIHYPERLIPIDEMIC	378,776	505	21.9	5,464	0.7	95	69
ANALGESICS - Narcotic	361,991	1,279	55.4	13,234	0.8	36	27
ANTIHYPERTENSIVE	310,337	1,173	50.8	12,308	0.8	31	25
Total	7,604,424	10,083		107,928	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for Georgia, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 1,509 beneficiaries who were in nursing facilities for part of their enrollment and their 14,556 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Nondual Beneficiaries

TABLE ND.10A
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST
 AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, GEORGIA, 2005

Beneficiary Characteristics	All Top 10 Drug Groups			ANTIPSYCHOTICS				ANTICONVULSANT				
	Number of Rx	Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$
All	90,694	\$7,604,424	1,364	59.1	14,966	0.8	\$169	1,239	53.7	13,529	1.0	\$75
Female												
All Females	51,540	4,193,756	726	58.5	8,113	0.9	173	682	55.0	7,488	1.0	75
Female, Disabled												
All Ages	41,754	3,530,231	581	61.8	6,516	0.9	183	610	64.9	6,749	1.0	77
64 or younger	35,907	3,111,989	495	61.6	5,548	0.9	191	537	66.8	5,953	1.0	81
65-74	4,129	288,512	57	62.6	639	0.8	142	54	59.3	586	0.9	49
75-84	1,531	116,088	25	69.4	287	0.9	139	17	47.2	188	0.8	44
85 and older	187	13,642	4	44.4	42	0.6	106	2	22.2	22	0.5	17
Female, Other Eligibles												
All Ages	9,786	663,525	145	48.3	1,597	0.8	130	72	24.0	739	1.0	61
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	2,529	189,108	37	68.5	423	0.9	182	23	42.6	260	0.7	44
75-84	3,810	262,118	64	64.6	707	0.8	119	28	28.3	272	1.2	51
85 and older	3,447	212,299	44	30.1	467	0.8	101	21	14.4	207	1.1	97
Male												
All Males	39,154	3,410,668	638	59.7	6,853	0.8	165	557	52.2	6,041	1.0	75
Male, Disabled												
All Ages	33,242	2,986,255	553	63.2	5,941	0.8	169	498	56.9	5,412	1.0	77
64 or younger	30,978	2,757,617	500	61.5	5,322	0.8	165	479	58.9	5,200	1.0	77
65-74	1,939	201,637	45	93.8	523	0.8	218	19	39.6	212	0.8	79
75-84	232	21,338	5	45.5	60	0.6	110	0	0.0	0	0.0	0
85 and older	93	5,663	3	100.0	36	0.5	65	0	0.0	0	0.0	0
Male, Other Eligibles												
All Ages	5,912	424,413	85	44.0	912	0.8	141	59	30.6	629	0.9	58
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	2,014	146,709	35	67.3	379	0.8	152	28	53.8	287	1.0	58
75-84	2,438	179,408	36	43.9	384	0.9	138	25	30.5	280	0.9	65
85 and older	1,460	98,296	14	23.7	149	0.8	120	6	10.2	62	0.7	26
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Georgia, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 1,509 beneficiaries who were in nursing facilities for part of their enrollment and their 14,556 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispn.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, GEORGIA, 2005

Beneficiary Characteristics	ANTIDEPRESSANTS					ANTIDIABETIC					ULCER DRUGS				
	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$
All	1,482	64.2	15,949	0.8	\$50	1,151	49.9	12,338	1.0	\$51	1,389	60.2	14,867	0.8	\$36
Female															
All Females	867	69.9	9,420	0.8	50	728	58.7	7,707	1.0	51	756	61.0	8,085	0.8	36
Female, Disabled															
All Ages	684	72.8	7,478	0.8	53	582	61.9	6,262	1.0	52	598	63.6	6,420	0.8	37
64 or younger	604	75.1	6,624	0.8	53	480	59.7	5,221	1.0	53	500	62.2	5,363	0.8	37
65-74	53	58.2	561	0.8	51	68	74.7	704	0.9	47	72	79.1	768	0.7	40
75-84	22	61.1	235	0.8	52	30	83.3	321	0.8	52	21	58.3	240	0.7	39
85 and older	5	55.6	58	0.7	60	4	44.4	16	0.6	24	5	55.6	49	0.8	14
Female, Other Eligibles															
All Ages	183	61.0	1,942	0.8	42	146	48.7	1,445	1.0	49	158	52.7	1,665	0.8	32
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	46	85.2	498	0.8	44	46	85.2	490	1.0	52	37	68.5	416	0.8	44
75-84	66	66.7	717	0.8	48	46	46.5	477	1.1	50	52	52.5	566	0.7	28
85 and older	71	48.6	727	0.8	35	54	37.0	478	0.9	44	69	47.3	683	0.8	29
Male															
All Males	615	57.6	6,529	0.8	49	423	39.6	4,631	1.0	50	633	59.3	6,782	0.8	37
Male, Disabled															
All Ages	517	59.1	5,504	0.8	49	348	39.8	3,812	1.0	51	535	61.1	5,740	0.8	37
64 or younger	490	60.3	5,196	0.8	49	315	38.7	3,430	1.0	51	500	61.5	5,350	0.8	37
65-74	21	43.8	236	0.8	59	30	62.5	346	0.9	41	28	58.3	306	0.8	29
75-84	4	36.4	48	0.8	36	3	27.3	36	0.7	71	4	36.4	48	0.5	54
85 and older	2	66.7	24	0.8	28	0	0.0	0	0.0	0	3	100.0	36	0.6	32
Male, Other Eligibles															
All Ages	98	50.8	1,025	0.8	47	75	38.9	819	0.9	45	98	50.8	1,042	0.8	35
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	35	67.3	356	0.8	43	33	63.5	354	0.9	42	28	53.8	295	0.7	37
75-84	37	45.1	394	0.8	45	29	35.4	322	0.9	47	39	47.6	406	0.7	36
85 and older	26	44.1	275	0.8	54	13	22.0	143	0.9	50	31	52.5	341	0.8	32
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Georgia, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 1,509 beneficiaries who were in nursing facilities for part of their enrollment and their 14,556 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10C
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, GEORGIA, 2005

Beneficiary Characteristics	ANTIVIRAL					MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL					ANTIHYPERLIPIDEMIC				
	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$
All	163	7.1	1,727	0.6	\$297	338	14.6	3,546	0.8	\$152	505	21.9	5,464	0.7	\$69
Female															
All Females	64	5.2	674	0.4	182	214	17.3	2,210	0.8	162	280	22.6	3,026	0.7	67
Female, Disabled															
All Ages	53	5.6	557	0.5	217	120	12.8	1,285	0.8	203	220	23.4	2,400	0.7	69
64 or younger	52	6.5	545	0.5	222	86	10.7	923	0.8	240	180	22.4	1,968	0.7	68
65-74	1	1.1	12	0.1	1	17	18.7	196	0.8	115	29	31.9	310	0.8	77
75-84	0	0.0	0	0.0	0	14	38.9	133	0.7	101	11	30.6	122	0.8	71
85 and older	0	0.0	0	0.0	0	3	33.3	33	0.8	114	0	0.0	0	0.0	0
Female, Other Eligibles															
All Ages	11	3.7	117	0.1	16	94	31.3	925	0.8	106	60	20.0	626	0.7	57
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	2	3.7	24	0.2	33	11	20.4	126	0.6	79	15	27.8	174	0.8	72
75-84	2	2.0	16	0.2	21	51	51.5	516	0.8	107	28	28.3	296	0.7	52
85 and older	7	4.8	77	0.1	9	32	21.9	283	0.8	117	17	11.6	156	0.6	51
Male															
All Males	99	9.3	1,053	0.7	371	124	11.6	1,336	0.8	135	225	21.1	2,438	0.8	73
Male, Disabled															
All Ages	92	10.5	973	0.8	401	75	8.6	832	0.8	143	187	21.4	2,026	0.7	71
64 or younger	90	11.1	949	0.8	411	63	7.7	699	0.8	150	170	20.9	1,825	0.7	72
65-74	0	0.0	0	0.0	0	8	16.7	85	0.8	120	15	31.3	177	0.6	58
75-84	0	0.0	0	0.0	0	3	27.3	36	0.7	79	2	18.2	24	0.8	85
85 and older	2	66.7	24	0.1	4	1	33.3	12	0.6	95	0	0.0	0	0.0	0
Male, Other Eligibles															
All Ages	7	3.6	80	0.1	7	49	25.4	504	0.9	123	38	19.7	412	0.9	83
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	1	1.9	12	0.3	18	10	19.2	105	0.8	108	13	25.0	135	0.7	70
75-84	3	3.7	36	0.1	5	20	24.4	199	0.9	120	19	23.2	212	0.9	91
85 and older	3	5.1	32	0.1	6	19	32.2	200	0.9	134	6	10.2	65	0.8	83
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Georgia, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 1,509 beneficiaries who were in nursing facilities for part of their enrollment and their 14,556 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10D
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS
 SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, GEORGIA, 2005

Beneficiary Characteristics	ANALGESICS - Narcotic						ANTIHYPERTENSIVE					
	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	All-Year Nursing Facility Residents	Benefit Months Among All-Year Nursing Facility Residents
All	1,279	55.4	13,234	0.8	\$27	1,173	50.8	12,308	0.8	\$25	2,308	23,300
Female												
All Females	739	59.6	7,652	0.8	29	606	48.9	6,354	0.8	26	1,240	12,655
Female, Disabled												
All Ages	586	62.3	6,076	0.8	32	445	47.3	4,692	0.8	27	940	9,698
64 or younger	504	62.7	5,277	0.8	33	360	44.8	3,796	0.8	28	804	8,272
65-74	62	68.1	603	0.8	25	63	69.2	661	0.8	23	91	948
75-84	16	44.4	158	0.7	20	19	52.8	215	0.9	22	36	391
85 and older	4	44.4	38	0.3	8	3	33.3	20	1.1	11	9	87
Female, Other Eligibles												
All Ages	153	51.0	1,576	0.6	18	161	53.7	1,662	0.8	24	300	2,957
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	2
65-74	31	57.4	333	0.6	6	31	57.4	343	1.0	29	54	578
75-84	47	47.5	502	0.6	13	57	57.6	622	0.8	20	99	1,031
85 and older	75	51.4	741	0.7	26	73	50.0	697	0.8	26	146	1,346
Male												
All Males	540	50.6	5,582	0.7	25	567	53.1	5,954	0.8	24	1,068	10,645
Male, Disabled												
All Ages	467	53.4	4,858	0.7	26	454	51.9	4,778	0.8	25	875	8,731
64 or younger	443	54.5	4,620	0.7	26	411	50.6	4,287	0.8	25	813	8,056
65-74	20	41.7	190	0.8	31	29	60.4	334	0.9	24	48	518
75-84	3	27.3	36	0.1	1	12	109.1	133	0.5	22	11	121
85 and older	1	33.3	12	0.5	3	2	66.7	24	0.9	10	3	36
Male, Other Eligibles												
All Ages	73	37.8	724	0.6	21	113	58.5	1,176	0.8	22	193	1,914
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
65-74	28	53.8	280	0.4	5	41	78.8	413	0.8	22	52	490
75-84	24	29.3	241	0.7	29	45	54.9	488	0.8	20	82	825
85 and older	21	35.6	203	0.9	31	27	45.8	275	0.9	26	59	599
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

Source: Data for this table are from the MAX 2005 file for Georgia, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 1,509 beneficiaries who were in nursing facilities for part of their enrollment and their 14,556 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.11
USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC^{a,b}
GEORGIA, 2005

Beneficiary Characteristics	Number of Beneficiaries with at Least One Part D Excluded Rx	Percentage of Beneficiaries with at Least One Part D Excluded Rx	Number of Part D Excluded Rx per Beneficiary	Total Number Part D Excluded Rx	Part D Excluded Rx \$ per Beneficiary	Total Part D Excluded Rx \$	\$ per Part D Excluded Rx	Part D Excluded Rx \$ as a Percentage of All Nondual Rx \$	Total Number of Beneficiaries
All	466,888	29.7	0.8	1,206,157	\$14	\$21,847,488	\$18	3.2	1,574,358
Age									
5 and younger	204,610	40.1	0.9	468,831	15	7,793,542	17	7.2	510,763
6-14	125,339	27.5	0.6	270,461	12	5,686,355	21	4.4	455,072
15-20	47,648	21.9	0.5	102,963	10	2,222,104	22	3.1	217,570
21-44	58,389	19.1	0.6	170,984	10	3,181,336	19	1.8	305,564
45-64	28,553	36.3	2.3	177,782	36	2,804,631	16	1.6	78,739
65-74	1,251	34.8	2.2	7,889	23	82,669	10	1.1	3,593
75-84	743	34.8	2.3	4,826	24	51,770	11	1.3	2,132
85 and older	355	38.4	2.6	2,421	27	25,081	10	1.7	924
Unknown	0	0.0	0.0	0	0	0	0	0.0	1
Basis of Eligibility^c									
Aged	1,217	30.6	1.8	7,178	19	75,658	11	1.2	3,978
Disabled	56,814	35.5	1.9	301,056	44	6,995,942	23	2.0	159,942
Adults	59,029	18.8	0.4	135,386	5	1,698,068	13	1.7	314,160
Children	348,924	31.9	0.7	759,378	12	13,041,174	17	5.8	1,093,012
Unknown	904	27.7	1.0	3,159	11	36,646	12	0.9	3,266
Gender									
Female	266,243	29.1	0.8	702,895	13	12,277,522	17	3.2	915,031
Male	200,632	30.4	0.8	503,231	15	9,569,453	19	3.3	659,271
Unknown	13	23.2	0.6	31	9	513	17	8.3	56
Race									
White	220,370	34.4	0.9	598,796	17	10,860,429	18	3.5	640,303
African American	198,977	25.2	0.6	469,565	10	8,045,615	17	3.0	788,118
Other/unknown	47,541	32.6	0.9	137,796	20	2,941,444	21	3.1	145,937
Use of Nursing Facilities^d									
Entire year	1,423	61.7	6.2	14,266	78	180,518	13	1.6	2,308
Part year	1,029	68.2	5.3	7,999	153	231,435	29	3.6	1,509
None	464,436	29.6	0.8	1,183,892	14	21,435,535	18	3.3	1,570,541
Maintenance Assistance Status									
Cash	153,690	30.2	1.0	517,516	20	9,977,160	19	2.4	508,162
Medically needy	1,288	28.5	1.2	5,530	61	276,222	50	4.1	4,516
Poverty related	232,525	29.9	0.6	496,421	11	8,167,694	16	5.5	777,811
Other/unknown	79,385	28.0	0.7	186,690	12	3,426,412	18	3.4	283,869

Source: Data for this table are from the MAX 2005 file for Georgia, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005.

b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12
USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}
GEORGIA, 2005

Beneficiary Characteristics	Number Rx per Benefit Month	Rx \$ per Benefit Month	\$ per Rx	Barbiturate \$ per Benefit Month	Benzodiazepine \$ per Benefit Month	Number of Benefit Months
All	0.1	\$2	\$18	\$0	\$0	13,818,465
Age						
5 and younger	0.1	2	17	0	0	4,497,323
6-14	0.1	1	21	0	0	4,300,775
15-20	0.1	1	22	0	0	1,899,260
21-44	0.1	1	19	0	0	2,315,652
45-64	0.2	4	16	0	1	741,208
65-74	0.2	2	10	0	0	34,401
75-84	0.2	2	11	0	0	21,195
85 and older	0.3	3	10	0	0	8,648
Unknown	0.0	0	0	0	0	3
Basis of Eligibility^c						
Aged	0.2	2	11	0	0	36,399
Disabled	0.2	4	23	0	1	1,658,859
Adults	0.1	1	13	0	0	2,236,667
Children	0.1	1	17	0	0	9,854,074
Unknown	0.1	1	12	0	0	32,466
Gender						
Female	0.1	2	17	0	0	7,864,913
Male	0.1	2	19	0	0	5,953,123
Unknown	0.1	1	17	0	0	429
Race						
White	0.1	2	18	0	0	5,413,077
African American	0.1	1	17	0	0	7,133,017
Other/unknown	0.1	2	21	0	1	1,272,371
Use of Nursing Facilities^d						
Entire year	0.6	8	13	0	3	23,300
Part year	0.5	16	29	0	3	14,556
None	0.1	2	18	0	0	13,780,609
Maintenance Assistance Status						
Cash	0.1	2	19	0	0	4,794,088
Medically needy	0.2	11	50	0	1	25,666
Poverty related	0.1	1	16	0	0	6,654,526
Other/unknown	0.1	1	18	0	0	2,344,185

Source: Data for this table are from the MAX 2005 file for Georgia, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.12 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005.

b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

TABLE ND.13
USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS^{a,b,c}
GEORGIA, 2005

Drug Category	Number of Users	Rx \$ per User	Total Rx \$	Rx \$ as a Percentage of All Part D		\$ per Rx	Number Rx as a Percentage of All Part D	
				Excluded Rx \$	Total Number Rx.		Excluded Rx	Total Number Rx.
All	543,236	\$40	\$21,847,488	100.0	1,206,157	\$18	100.0	1,206,157
Anorexia or weight loss/gain	47	326	15,341	0.1	121	127	0.0	121
Fertility drugs	2	58	115	0.0	2	58	0.0	2
Drugs for cosmetic purposes	250	13	3,180	0.0	350	9	0.0	350
Cough and cold medications	323,903	34	10,944,271	50.1	632,070	17	52.4	1,264,140
Vitamins and minerals	21,473	72	1,539,787	7.0	88,986	17	7.4	109,959
Non-prescription drugs	136,638	20	2,684,707	12.3	272,056	10	22.6	308,692
Barbiturates	3,026	44	132,572	0.6	23,023	6	1.9	38,039
Benzodiazepines	42,434	72	3,050,009	14.0	155,084	20	12.9	199,118
Other Part D Excl Rx Drugs	15,463	225	3,477,506	15.9	34,465	101	2.9	58,930

Source: Data for this table are from the MAX 2005 file for Georgia, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.13 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2005. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.

b. Includes OTC drugs as well as prescription drugs.

c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Nondual Beneficiaries

APPENDIX TABLE A.1
CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{a, b}
NONDUAL BENEFICIARIES, GEORGIA, 2005

Beneficiary Characteristics	Number of Beneficiaries						Number of Benefit Months					
	All	Aged	Blind/ Disabled	Adults	Children	Other/ Unknown	All	Aged	Blind/ Disabled	Adults	Children	Other/ Unknown
All	1,574,358	3,978	159,942	314,160	1,093,012	3,266	13,818,465	36,399	1,658,859	2,236,667	9,854,074	32,466
Age												
5 and younger	510,763	0	10,953	57	499,752	1	4,497,323	0	114,122	336	4,382,853	12
6-14	455,072	0	25,022	206	429,844	0	4,300,775	0	276,409	1,278	4,023,088	0
15-20	217,570	0	16,710	38,154	162,615	91	1,899,260	0	183,398	274,265	1,440,843	754
21-44	305,564	0	43,857	259,236	773	1,698	2,315,652	0	455,884	1,836,240	7,029	16,499
45-64	78,739	0	60,793	16,468	14	1,464	741,208	0	601,673	124,329	128	15,078
65-74	3,593	1,553	1,997	31	0	12	34,401	13,469	20,640	169	0	123
75-84	2,132	1,623	506	3	0	0	21,195	15,561	5,612	22	0	0
85 and older	924	802	104	5	13	0	8,648	7,369	1,121	28	130	0
Unknown	1	0	0	0	1	0	3	0	0	0	3	0
Gender												
Female	915,031	2,543	81,085	287,166	540,974	3,263	7,864,913	23,413	852,025	2,065,694	4,891,334	32,447
Male	659,271	1,434	78,857	26,989	551,988	3	5,953,123	12,984	806,834	170,946	4,962,340	19
Unknown	56	1	0	5	50	0	429	2	0	27	400	0
Race												
White	640,303	1,262	53,009	138,884	445,424	1,724	5,413,077	10,587	535,685	917,449	3,932,047	17,309
African American	788,118	1,345	69,960	166,530	549,159	1,124	7,133,017	12,237	731,876	1,269,659	5,108,212	11,033
Other/unknown	145,937	1,371	36,973	8,746	98,429	418	1,272,371	13,575	391,298	49,559	813,815	4,124
Use of Nursing Facilities^c												
Entire year	2,308	492	1,815	1	0	0	23,300	4,869	18,429	2	0	0
Part year	1,509	271	1,223	13	1	1	14,556	2,268	12,155	112	9	12
None	1,570,541	3,215	156,904	314,146	1,093,011	3,265	13,780,609	29,262	1,628,275	2,236,553	9,854,065	32,454
Maintenance Assistance Status												
Cash	508,162	1,484	136,983	132,942	236,753	0	4,794,088	16,100	1,470,250	1,034,951	2,272,787	0
Medically needy	4,516	1,094	3,366	7	49	0	25,666	8,568	16,933	17	148	0
Poverty related	777,811	15	45	119,078	655,407	3,266	6,654,526	158	409	696,518	5,924,975	32,466
Other/unknown	283,869	1,385	19,548	62,133	200,803	0	2,344,185	11,573	171,267	505,181	1,656,164	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	1,574,358	3,978	159,942	314,160	1,093,012	3,266	13,818,465	36,399	1,658,859	2,236,667	9,854,074	32,466
FFS part year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
MC all year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
MC all year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0

Source: Data for this table are from the MAX 2005 file for Georgia, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2
 MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS^a
 NONDUAL BENEFICIARIES, GEORGIA, 2005

	Beneficiaries and Benefit Months in Cell J of Table 1		Included in Cell K of Table 1		Excluded from Cell K of Table 1	
	Number of Beneficiaries	Number of Benefit Months	Number of Beneficiaries	Number of Benefit Months	Number of Beneficiaries	Number of Benefit Months
All	1,574,358	13,818,465	1,574,358	13,818,465	0	0
Fee-for-service (FFS) all year	1,574,358	13,818,465	1,574,358	13,818,465	0	0
FFS part year, with Rx claims	0	0	0	0	0	0
FFS part year, with no Rx claims	0	0	0	0	0	0
Managed care (MC) all year, with Rx claims	0	0	0	0	0	0
MC all year, with no Rx claims	0	0	0	0	0	0

Source: Data for this table are from the MAX 2005 file for Georgia, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract;

MC = managed care; Rx = pharmacy benefit.

Nondual Beneficiaries